CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...